权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

IMMUNOCHEMICAL MARKER FOR TUMOR HYPOXIA

肿瘤缺氧的免疫化学标志物

基本信息

批准号：
2545398
负责人：
JAMES ARTHUR RALEIGH
金额：
$ 19.63万
依托单位：
NATURAL PHARMACIA INTERNATIONAL, INC.
依托单位国家：
美国
项目类别：
财政年份：
1996
资助国家：
美国
起止时间：
1996-03-01 至 1998-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2545398
关键词：
artificial intelligence azoles biomarker carcinoma cervix neoplasms computer assisted diagnosis computer system design /evaluation diagnosis design /evaluation enzyme linked immunosorbent assay human subject hypoxia image processing immunocytochemistry monoclonal antibody neoplasm /cancer immunodiagnosis

项目摘要

Low tissue oxygen concentration or hypoxia occurs with cancer and cardiovascular disease and plays a role in diabetes and alcohol-induced liver disease. Hypoxic tumor cells are important because they resist both radiation and drug treatment. Hyperbaric oxygen, radiosensitizers, hypoxic cell cytotoxins and neutron irradiation are used to get around this resistance but hypoxia is rarely monitored so patients who might benefit are not selected and the reason for success or failure of these costly therapies is not known. The immunostaining, marker method is ideal for measuring tumor hypoxia. The marker is injected into cervix, head and neck and breast cancer patients and biopsy samples taken 24 hours later. Immunostaining of formalin-fixed, tissue sections reveals hypoxia and standard image analysis methods measure its extent. The marker method could be of enormous value in treatment planning for cancer patients and could also be used in animal studies of liver damage, stroke, cardiac arrest, diabetes, etc. PROPOSED COMMERCIAL APPLICATION: Potential commercial applications include routine use in conventional radiation therapy (potential up to 300,000 patients/year in US); in experimental therapies based on hypoxia in human tumors; in experimental models of tumor hypoxia, stroke, cardiac failure, liver disease, wound healing, angiogenesis and normal tissue development.

低组织氧浓度或缺氧发生于癌症，心血管疾病，并在糖尿病和酒精引起的肝脏疾病低分化肿瘤细胞很重要，因为它们抵抗放射治疗和药物治疗。高压氧，放射增敏剂，缺氧细胞细胞毒素和中子辐射被用来四处走动这种阻力，但缺氧很少监测，所以病人谁可能利益没有被选中，成功或失败的原因，这些昂贵的治疗是未知的。免疫染色标记方法是理想的用于测量肿瘤缺氧。将标记物注射到子宫颈、头部以及颈部和乳腺癌患者和24小时内采集的活检样本后福尔马林固定的组织切片的免疫染色显示缺氧并且标准图像分析方法测量其程度。标记法在癌症患者的治疗计划中可能具有巨大的价值，也可用于肝损伤、中风、心脏病、心脏骤停、糖尿病等拟议的商业应用：潜在的商业应用包括常规放射治疗中常规使用（可能高达 300，000例患者/年（美国）;在基于缺氧的实验性治疗中在人类肿瘤中;在肿瘤缺氧、中风、心脏病的实验模型中衰竭、肝脏疾病、伤口愈合、血管生成和正常组织发展

项目成果

期刊论文数量（13）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin.

DOI：
发表时间：
2003-10
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
0
作者：
Y. Azuma;S. Chou;R. Lininger;B. Murphy;M. Varia;J. Raleigh
通讯作者：
Y. Azuma;S. Chou;R. Lininger;B. Murphy;M. Varia;J. Raleigh

Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.

DOI：
发表时间：
2005
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
0
作者：
M. Arcasoy;K. Amin;S. Chou;Z. Haroon;M. Varia;J. Raleigh
通讯作者：
M. Arcasoy;K. Amin;S. Chou;Z. Haroon;M. Varia;J. Raleigh

Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas.

DOI：
10.1038/sj.bjc.6601585
发表时间：
2004-02-09
期刊：
British journal of cancer
影响因子：
8.8
作者：
通讯作者：

A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas.

鳞状细胞癌缺氧与金属硫蛋白蛋白表达的临床研究。

DOI：
发表时间：
2000
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
0
作者：
Raleigh,JA;Chou,SC;Calkins-Adams,DP;Ballenger,CA;Novotny,DB;Varia,MA
通讯作者：
Varia,MA

Reperfusion injury in livers due to gentle in situ organ manipulation during harvest involves hypoxia and free radicals.

收获过程中温和的原位器官操作导致肝脏再灌注损伤，涉及缺氧和自由基。